Home › Program & Process Development

AAV Gene Therapy Program & Process Development

Accelerate your AAV Gene Therapy program
Construct design through BLA

CMC for your Gene Therapy Product

Accelerating Commercialization from Ultra Rare to Broad Market Indications

Our team brings extensive experience with established serotypes (AAV2, AAV5, AAV8, AAV9) and next-generation novel capsids. We refine development strategies to maximize step yield, purification efficiency, and optimize empty/full capsid ratios, proactively solving critical CMC challenges that delay IND filings.

We provide specialized CMC roadmaps for products eligible for accelerated development pathways, including:

  • Fast Track: Streamlining development for unmet medical needs.
  • Breakthrough Therapy: Intensifying FDA guidance for substantial clinical improvements.
  • RMAT: Navigating the specific hurdles of Regenerative Medicine Advanced Therapies.
🧬

AAV Gene Therapy Process Development Services

Specialized capabilities for adeno-associated virus development across all platforms and serotypes

From AAV construct design to clinical manufacturing, our consultants offer end-to-end bioprocessing expertise. We specialize in producer cell lines, triple plasmid transfection, and baculovirus production, seamlessly scaling your processes up to 500L bioreactors with robust scalable downstream purification strategies built in.

🧬   Construct Design
🧬   Transient Transfection Optimization
🧬   Baculovirus Platform Transfer
🧬   Producer Cell Line Development
🧬   Suspension Scale-Up (adherent → suspension)
🧬   Downstream Purification Strategy
🧬   Viral Clearance Study Design
🧬   Empty/Full Capsid Ratio Control
🧬  Module 3 Authorship
A Phase-Appropriate CMC Approach

Cutting Out Excess & Risks at Every Stage

Fast-tracking drug development and optimizing patient safety, production efficiency, and supply reliability to accelerate market access for AAV gene therapies and biologics.

Pre-Clinical
Begin with the Commercial End State in Mind

Construct design through toxicology lot production, IND authorship & AAV platform selection

→   Construct Design / Plasmid Manufacturing
→   AAV Serotype Selection & Capsid Engineering Support
→   Triple Plasmid System Design & Optimization
→   Producer Cell Line Development (Stable or Transient)
→   AAV Upstream Development (Adherent to Suspension Adaption)
→   AAV Purification Strategy (Affinity, Ion Exchange, Ultracentrifugation)
→   Empty/Full Capsid Ratio Optimization
→   Process Mapping / Supply Planning
→   Statistical Support and Design of Experiments
→   IND Authorship and Support
→   Manufacturing Process Development and Product Characterization
→   Toxicology Lot Production
Phase 1 / 2
Lay the Groundwork for Reliable Clinical Supply

Tech transfer, scale-up, CDMO selection & IND amendment support

→   Detailed Process Description and Sampling Plan development
→   Media Optimization, Spent Media Analysis, Metabolite Analysis
→   RFP / Vendor Selection Support
→   AAV Harvest and Clarification Optimization
→   Tech Transfer of Manufacturing Process
→   Downstream Process Intensification for AAV Purification
→   Facility Fit Assessment
→   AAV Formulation & Fill-Finish Development
→   Scale Up of Manufacturing Process
→   Operational Excellence
→   Person In Plant Support
→   Drug Product Packaging / Kitting Release
→   Clinical Batch Release
→   Drug Product Device Compatibility / Design
→   Stability Study design
→   Type B and C FDA meeting support
→   Raw Material Risk/Gap Assessment
→   Comparability Protocol and Report
→   Process Change Risk Assessment
→   Residuals Analysis
→   GMP Cell Banking
Pre-Commercial Launch
Ensure Process Control & Submission Readiness

PPQ, BLA filing, process characterization & viral clearance studies

→   Process Characterization Study Design
→   Equipment/Site Validation
→   AAV Process Characterization Including Multivariate Analysis
→   Site Master File Preparation
→   Scale Down Model Qualification
→   Shipping Validation Study Support
→   Historical Process Performance Analytics
→   End of Production Cell Bank
→   Failure Mode Effect Analysis (FMEA) Drafting
→   Resin Lifetime Study Support
→   Process Control Strategy Drafting
→   Leachable Extractable and Impurity Clearance Protocols
→   Process Validation Master Plan Drafting
→   Pre-Approval Inspection Readiness
→   Process Validation Protocol Drafting
→   Briefing Book Drafting
→   Residual Plasmid DNA & Host Cell Protein Clearance Validation
→   BLA Submission Filing Support
→   Commercial Master Batch Record / Sample Plan Drafting
→   Process Performance Qualification (PPQ)
→   Gene Therapy-Specific Viral Clearance Studies
→   Container Closure and Packaging Validation
→   Bio-Burden / Contamination Control Mitigation Strategy / TSE BSE
→   Shipping Validation
→   Mixing Studies / Media and Buffer Hold
Post-Commercial
Maintain Compliance & Expand Your Market

Continuous process validation, lifecycle management & site tech transfer

→   Continuous Process Validation Protocol Drafting
→   Post Approval Inspection Mitigation
→   Continuous Process Validation Data Analysis and Maintenance
→   Market Expansion Filing Support
→   Commercial Site/Tech Transfer and Comparability Support
→   Competitive intelligence and Due Diligence for investors.
→   Commercial Batch Disposition and Release Support
AAV Manufacturing Expertise

Specialized Viral Vector Process Development

Our process development services are designed to accelerate market access by fast-tracking drug development while prioritizing patient safety, production efficiency, and supply reliability. We leverage platform-agnostic expertise across both human (HEK293) and insect (Sf9) cell lines, navigating diverse production modalities ranging from stable producer lines and plasmid transfection to viral infection systems like HSV and Baculovirus.

Our integrated approach encompasses comprehensive upstream optimization including media screening, serum-free adaptation, and transfection complexation and robust downstream purification using methodologies like CsCl gradient ultracentrifugation, affinity and ion exchange chromatography. To ensure a seamless transition to the clinic and beyond, we provide specialized formulation development for cryogenic storage.

AAV2

AAV5

AAV8

AAV9

AAVrh10

Novel Capsids

🏭

Triple Plasmid vs. HSV vs. Baculovirus Platforms

Comparative platform assessment, technology transfer packages, and manufacturing robustness evaluation for HEK293 and Sf9 cell-based systems

⚗️

Upstream Bioreactor Scale-Up

Adherent to suspension adaptation, bioreactor optimization (wave, stirred-tank), MOI and infection timing studies, and cell viability management

🔬

Downstream Purification Strategy

Ultracentrifugation, iodixanol gradient, affinity chromatography (AAVX, AVB Sepharose), and ion-exchange polishing platform and custom approaches

📊

Empty/Full Capsid Control & Optimization

Analytical ultracentrifugation (AUC), AEX chromatography strategies, and process modification to achieve target full capsid percentage specifications

📋

IND CMC Module 3 Authorship

DS and DP process description, characterization, control strategy, and container closure system for gene therapy

Rational Design, Reliable Results

Emphasizing Process Design & Product Quality

Our core principles drive measurable outcomes for AAV gene therapy and biologics programs at every stage.

🏆
High Product Quality

Achieve superior quality attributes with our specialized viral vector downstream processing strategies. We optimize chromatography steps for AAV purification and design AAV manufacturing process characterization studies to minimize impurities

⚡
Timeline Acceleration

Expedite your timeline with expert viral vector scale-up strategy, from triple transfection optimization to AAV suspension cell culture.
Our approach accelerates gene therapy IND CMC section authoring and AAV packaging capacity optimization to get you to the clinic sooner.

🔗
Commercial Supply Reliability & Validation

Ensure consistent supply with our AAV platform approach covering development from vial thaw to viral vector fill-finish. We guide you through PPQ strategy and late-phase validation to secure commercial readiness.

🛡️
Proven Technologies

We balance innovation in novel capsids with the stability of proven manufacturing platforms. De-risk your program by leveraging robust viral vector downstream processing technologies and production methods.

📑
Regulatory Alignment

Deep knowledge of FDA and EMA gene therapy CMC expectations, ICH and current CBER guidance for viral vectors.

🤝
CDMO Partnership Support

End-to-end CDMO selection, RFP management, technical due diligence, and tech transfer oversight for AAV and biologics manufacturing.

Connect With Our Team Today

Advance Your Drug Program with Confidence

Start building reliable, high-quality drug development programs today.